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A b s t r a c t  
Matrix tablets were prepared using blends of xanthan gum (XG), Guar gum (GG) and ethylcellulose 
(EC). The polymers were combined using six different ratios; 1:1:1, 1:2:1, 1:2:2, 2:2:1, 2:1:2 and 
2:1:1 to produce formulations XG1GG1EC1, XG1GG2EC1, XG1GG2EC2, XG2GG2EC1. 
XG2GG1EC2 and XG2GG1EC1 respectively. Metronidazole was used as the model drug. The 
ability of the prepared matrices to target drug release predominantly at the colon under the influence 
of colonic bacteria was evaluated using the dissolution medium containing 4 % caecal content. Our 
results show that, optimum drug release was observed with formulations XG2GG2EC1 and 
XG2GG1EC1 with Cmax of 60 and 76 % respectively.  Significant difference (P<0.05) was observed 
between drug release in dissolution medium with and without rat caecal contents for the batches of 
Metronidazole tablets. Formulations (XG2GG2EC1 and XG2GG1EC1) followed Higuchi square 
roots kinetics ( r2 =0.9942) via fickian diffusion ( n < 0.45 ) and Korsemeyer model (r2 = 0.9939) via 
non ă fickian diffusion (n > 0.45) respectively. 
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Introduction 
Colon-specific drug delivery has gained increased importance in 
the delivery of drugs for the treatment of local diseases associated 
with the colon, such as Crohn's disease, ulcerative colitis, 
colorectal cancer and amoebiasis [1] 
Metronidazole, the drug of choice for intestinal amoebiasis, has to 
be delivered to the colon for its effective action against .Entamoeba 
histolytica. Metronidazole is rapidly and completely absorbed after 
oral administration of conventional tablet dosage forms. Although 
these tablets provide a minimal amount of metronidazole for local 
action in the colon which is still effective in relief of amoebiasis, 
undesirable systemic side effects occur upon their administration 
[2]. Hence, the need for colon targeted delivery using 
biodegradable and other suitable polymers. 
Although, several researchers [3-9]have reported the suitability of 
ethylcellulose, guar and xanthan gums in colon drug delivery, there 
is dearth of information on the blends of these polymers in colon 
targeting.  
Literature search reveals that, these three polymers have never 
been investigated as blends for target delivery of metronidazole to 
the colon. The aim of the present study therefore, was to 
investigate the development of various metronidazole colon-
specific delivery systems that could be formulated by using single 
and ternary blends of ethylcellulose, guar and xanthan gums. 
Materials and methods 
Metronidazole, Ethylcellulose, Guar gum and xanthan gum were all 
purchased from Sigma Aldrich, USA .Lactose monohydrate and 
magnesium stearate were procured from BDH, England. All other 
chemicals used were of analytical grade.   
Methods   
Preparation of metronidazole matrix tablets    
The polymers (Xanthan gum, Guar gum and ethylcellulose) were 
included in the formulation in various proportions. The drug was 
geometrically blended with sufficient quantity of lactose and the 
polymer as stated in Table 1, using pestle and mortar. Mixing was 
maintained for 10 minutes and the powder mixtures stored in well-
closed specimen bottles. 
Direct compression method was used for making the tablets. 
Before each compression, the die (9.5 mm in diameter) and flat 
faced punches were lubricated with a 1 % w/v dispersion of 
magnesium stearate in chloroform. Compression was achieved 
using a single punch tableting machine ( THP Shangai, Tianxiang 
and Chentai Pharmaceutical Machinery Co.Ltd. China ) fitted with 
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Table 1: Composition of  Metronidazole  matrix tablets   
FORMULATIONS INGREDIENTS 
 API(mg) GG XG EC LACTOSE
XG1GG1EC1 200 20 20 20 240
XG1GG2EC1 200 15 30 15 240
XG1GG2EC2 200 12 24 24 240
XG2GG2EC1 200 24 24 12 240
XG2GG1EC2 200 24 12 24 240
XG2GG1EC1 200 30 15 15 240
Key: XG = Xanthan gum, GG = Guar gum, API = Active Pharmaceutical 
Ingredient  GG1 = 10 % Guar Gum, XG1 = 10 % Xanthan gum, EC1 = 10 
% Ethylcellulose 
 
Each drug compacts were stored in airtight specimen bottles and 
allowed to equilibrate 24 hours before further evaluations. 
Evaluation of powder mixtures    
The powder mixtures were evaluated for angle of repose [10] bulk 
density [11], tapped density, compressibility index and hausner 
ratio [12] for micromeritic properties.    
Evaluation of tablets   
Tablets were evaluated for thickness and hardness [13] as well as 
friability [14] and weight variation [15] using standard methods.  
Content uniformity was evaluated using the method described by 
the Indian Pharmacopoeia [16]. 
Preparation of rat cecal content medium 
The method of Emeje et al [22] was adopted for this study. Briefly, 
Wistar rats weighing 150-200g and maintained on a normal diet 
(soaked gram) were used. Forty-five minutes before the 
commencement of drug release studies, seven rats were killed by 
spinal traction. The abdomen were opened, the cecal were traced, 
ligated at both the ends, dissected, and immediately transferred 
into pH 7.4 buffer previously bubbled with nitrogen. The cecal bags 
were opened, their contents were individually weighed, pooled, and 
suspended in the buffer continuously bubbled with carbon dioxide. 
These were finally added to the dissolution media to give a final 
cecal dilution of 4%w/v, respectively. All the above procedures 
were carried out under carbon dioxide in order to maintain 
anaerobic conditions. In carrying out this study, ethical guidelines 
were adhered to in accordance with the „Principles of Laboratory 
Animal Care‰ [25] and institutional standard operating procedures 
after obtaining permission from the institutional animal ethics 
committee. 
In-vitro drug release studies 
The ability of matrix tablets of metronidazole to remain intact in the 
physiological environment of stomach and small intestine was 
assessed by mimicking mouth to colon transit. Drug release 
studies were carried out using USP XXIII dissolution apparatus 
(Apparatus 1, 100 rpm, 37.5oC) in 500 ml 0.1 N HCI for 2 h as the 
average gastric emptying time is 2h.. The dissolution medium was 
replaced with 500 mL of pH 7.4 phosphate buffer saline ( PBS) and 
the dissolution was continued for 24 h. A 5 ml of the sample was 
taken at the specified time period (1 h, 2 h, 4 h, 5 h, 8 h, 10 h, 12 h, 
and 16 h) and analyzed at 250nm for Metronidazole using a 
Shimadu UV Spectrophotometer (Shimadu, Japan with . A 5 ml 
volume of filtered, fresh dissolution medium was added to make 
the volume after each sample withdrawal [17]. 
The susceptibility of the matrix tablets to the enzymatic action of 
colonic bacteria was assessed by continuing the drug release 
studies in 100 mL of simulated colonic fluids ( pH 6.8 phosphate 
buffered saline containing 4 % w/v of caecal contents of rats 
treated) (18). The drug release studies were carried out in USP 
dissolution test apparatus (apparatus 1, 100 rpm, 37 oC) with slight 
modification. A beaker (capacity 150 mL) containing 100 mL of 
dissolution medium was immersed in the water contained in the 
1000 mL vessel, which in turn, was the water bath of the 
apparatus. The tablets, after completing the dissolution study in 0.1 
M HCl (2 h) and pH-7.4 phosphate buffer (3 h) were placed in the 
baskets of the apparatus and immersed in the dissolution medium 
containing rat caecal contents. The release studies were carried 
out up to 24 h and 1 ml samples were withdrawn at specified time 
intervals (6 h, 8 h, 10 h, 12 h, 16 h and 24 h) without a pre-filter 
and replaced with 1 ml of fresh phosphate buffer. Samples 
withdrawn were analyzed for drug content at 250 nm. 
Drug release kinetics   
To analyze the mechanism of drug release rate kinetics, the results 
of invitro release profile were plotted in various kinetic models like 
zero order, first order, Higuchi model and korsmeyer ă peppas [19].    
Results and Discussions 
The powder mixtures of all the formulations were evaluated for 
angle of repose, bulk density, tapped density, and Hausner ratio. 
The angle of repose was found to be 35 ă 41o. The bulk and 
tapped densities were found to be in the range of 0.522- 0.571 
gm/cc and 0.750 -0.833 gm/cc respectively. The Hausner ratio was 
found to be 1.3 to 1.5 indicating moderate flow characters of the 
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Table 2: Evaluation of Metronidazole matrix powder mix   
  
parameters Formulations 
  XG1GG1EC1 XG1GG2EC1 XG1GG2EC2 XG2GG2EC1 XG2GG1EC2 XG2GG1EC1
Angle of repose (0) 39.81 38.81 41.14 37.64 39.81 35.07
Bulk density (gm/cc) 0.571 0.545 0.522 0.545 0.536 0.545
Tapped density (gm/cc) 0.769 0.769 0.750 0.769 0.750 0.833
Hausner ratio 1.347 1.411 1.437 1.411 1.400 1.530
   
The hardness of the tablets for all the formulations was in the 
range of 4.4 - 4.7 kg/cm2. The uniformity weight of 20 tablets of all 
the formulations was within 5% deviation. The friability of all the 
formulation was less than 1 %. Drug content of all the formulations 
were found to be in the range of 98 to 99 % (table-3). All the results 
are within the prescribed limits [13].   
 
Table 3: Evaluation of Metronidazole  matrix tablets 
 
parameters Formulations 
  XG1GG1EC1 XG1GG2EC1 XG1GG2EC2 XG2GG2EC1 XG2GG1EC2 XG2GG1EC1
Hardness (kg/cm2) 4.6μ0.44 4.5μ0.44 4.4μ0.39 4.6μ0.39 4.7μ0.47 4.7μ0.58
Weight (mg) 496.9μ4.53 497.8μ5.61 496.6μ4.22 496.2μ3.99 497.7μ5.85 496.8μ5.30
Friability 0.4 0.8 0.8 0.4 0.8 0.8 
Drug content (%) 99 98 99.6 98 99 98.75
Thickness (mm) 4.91μ0.05 4.97μ0.02 4.95μ0.04 4.97μ0.03 4.98μ0.07 4.97μ0.02
Diameter (mm) 12.63μ0.02 12.65μ0.02 12.66μ0.01 12.69μ0.02 12.68μ0.01 12.69μ0.01
 
Dissolution profiles of Tablets 
The time taken for 50% and 70% of the drug to be released (T50% 
and T70%) respectively and the maximum cumulative amount of 
drug release (Cmax) were used to characterize the release profiles 
of the matrix tablets (Tables 4).All the batches except batches 
XG2GG2EC1 and XG2GG1EC1 were not able to retard the 
release of the drugs beyond 5h.During the in vitro drug release 
studies, all formulations were observed for physical integrity at 
different time intervals. All the formulations swelled and the outer 
layer of most of the tablets appeared to be hydrated after being 
placed in the dissolution medium, with progressive increase in the 
size of these hydrated matrices. There was also gel formation 
followed by gradual loss of integrity over a period, resulting from 
hydrodynamic stress induced by the dissolution apparatus. The 
quick hydration and subsequent gel formation is a foremost and 
important property of an excipient intended for use in sustained 
released formulations [18]. 
 
Table 4: Some Release parameters of Metronidazole Tablets 
parameters Formulations 
  XG1GG1EC1 XG1GG2EC1 XG1GG2EC2 XG2GG2EC1 XG2GG1EC2 XG2GG1EC1
T50  (h)  2.40 2.80 1.75 10.70 2.90  6.35
T70   (h) 4.80 4.50 3.90 - 4.60 11.40
Cmax  (%) 81.00 84.00 89.00 60.00 85.00 76.00
 
Table 5: Kinetics and mechanism of release for formulated metronidazole matrix tablets 
 
formulation,  Zero - order First ă order Higuchi Korsmeyer(n) 
XG2GG2EC1 0.9717 0.9897 0.9940 0.9928 (0.44) 
XG2GG1EC1 0.9574 0.9860 0.9889 0.9939(0.46) 
 
For matrices containing higher percentage of Xanthan gum 
(XG2GG1EC1 and XG2GG1EC2), there was an initial burst of 
Xanthan gum erosion from the matrices in the acidic pH, thereafter 
the erosion slowed considerably. Presence of Xanthan gum in 
combination with Guar gum in the tablets retarded the initial 
release of drugs from the tablets due to high swelling, which made 
them more vulnerable to digestion by the microbial enzymes in the 
colon (4). The Cmax values for XG1GG1EC1, XG1GG2EC1, 
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XG1GG2EC2, XG2GG2EC1. XG2GG1EC2 and XG2GG1EC1 
were 81%, 84.5%, 89 %, 60%, 85 % and 76 % respectively. There 
was significant difference (P<0.05) in the release profiles of 
XG2GG2EC1 and the other formulations (XG1GG1EC1, 
XG1GG2EC1, XG1GG2EC2. XG2GG1EC2 and XG2GG1EC1), 
which had no significant difference (P > 0.05) in their release 
profiles. Formulation with higher proportion of xanthan gum 
displayed higher retardation ability [23, 24]. 
Drug release studies with and without rat caecal content 
The susceptibility of Guar gum, Xanthan gum and ethylcellulose, to 
the enzymatic action of colonic bacteria, was assessed by 
continuing the drug release studies in rat caecal content medium 
for 24 h after 5 h of testing in simulated gastric and intestinal fluids.  
Figure 2 shows that the presence of rat caecal content in the 
dissolution medium resulted in a significant increase in drug 
release, when compared with control (P < 0.05). The cumulative 
percent of drug release from drug released after 24 h from 
XG2GG2EC1 and XG2GG1EC1 increased from 71.5% and 79.5% 
in the absence of rat caecal contents (control) to 89 % and 90 % 
(Figure 2) in the presence of rat caecal matter, respectively, 
indicating that polysaccharide metabolizing enzyme is present in 
the rat caecal contents. The implication is that the polymers used in 
the formulations were susceptible to the enzymatic action of 
colonic bacteria [4-9]. Therefore, these two formulations could be 
useful in targeting metronidazole to the colon. Although the use of 
polymers in drug delivery is not new, but formulators have devised 
means of circumventing the high cost of developing new excipients 
and the stringent regulatory requirements by combining existing 
and approved excipients. Some of these combinations have 
reportedly  shown better performance than the corresponding 
individual polymer. Various polymer blends have been studied in 
order to achieve their desired release kinetics (17). The presence 
of more than one polymer may result in spatial configuration, but it 
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Figure 2: Release profiles of Metronidazole Tablets with and without rat caecal content 
 
Matrix tablets were prepared using blends of Xanthan gum (XG), 
Guar gum (GG) and ethylcellulose (EC).Metronidazole was used 
as model drug. The ability of the prepared matrices to retard drug 
release in the upper gastrointestinal tract (GIT) and to undergo 
enzymatic hydrolysis by the colonic bacteria was evaluated. For 
this, drug release studies were carried out in the presence of rat 
caecal content.  Optimum release was observed with 
metronidazole formulations (XG2GG2EC1, XG2GG1EC1). 
Formulations containing the three polymers (XG2GG2EC1, 
XG2GG2EC1) had good drug retarding ability and were 
susceptible to degradation by colonic bacteria. They followed 
Higuchi square roots kinetics ( r2 =0.9942 ) via fickian diffusion ( n 
< 0.45 ) and Korsemeyer model (r2 = 0.9939) via non ă fickian 
diffusion (n > 0.45) respectively. 
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